Directed new share issue in Biotec Pharmacon ASA (NO) — NOK 23 million

Carnegie acted as sole bookrunner in the directed new share issue of 4.4 million new shares at a subscription price of NOK 5.25 per share. Biotec Pharmacon ASA is a biotechnology company developing, producing and marketing immune modulating beta-glucans and novel recombinant enzymes. June 2018.